Yuvezzi, a combination cholinergic agonist and alpha-adrenergic agonist, is now FDA-approved as a once-daily treatment for ...
The US Food and Drug Administration (FDA) has approved Cobenfy (Bristol Myers Squibb), a first-in-class antipsychotic approved for schizophrenia. The drug targets cholinergic receptors as opposed to ...
New M1 orthosteric agonist protects against scopolamine-induced damage in in vitro Alzheimer’s disease model Dec. 27, 2024 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results